CAI Company Profile and Key Details

Caris Life Sciences, Inc. (NASDAQ:CAI) closed at $26.05 USD, gaining $1.71 (7.03%) from the previous close of $24.34. The stock is currently mid-range between its 52-week high and low $14.19 and $34.54. With a market capitalization of about $7.36 billion, Caris Life Sciences, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~0.68). Key stats such as the average daily volume over the past year has been around 4.33 million shares, in line with its 52-week average. Headquartered in Irving, TX, Caris Life Sciences, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO David Dean Halbert, the company employs approximately 1,846 people and listed since June 18, 2025. Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally.

CAI has shown mixed momentum, gaining 2.62% over the past week and -16.6% over the past quarter, though year-to-date performance is down -2.63%. Short-term trend indicators are bullishly aligned (SMA20 -9.0%, SMA50 -22.14%, SMA200 -32.53%). The stock’s 14-day RSI is 34.48 (weak momentum), while the ATR of 1.28 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -54.73% below its high and over 12.19% above its low. Average 10-day trading volume of 3.37 million shares is below the 3-month average of 4.31 million, indicating normal recent market interest.

Caris Life Sciences, Inc. has 282.68 million shares outstanding. The public float is 134.86 million shares, elevated short interest at 11.88% of float. This equals 13.68 million shares. The short ratio is 2.39 days. Institutional investors hold 110.39% of the float. Insiders own 48.51%. Spetzler David Baxley holds 1.18 million shares, HALBERT JON has 704.60 thousand shares and Power Luke Thomas has 99.57 thousand shares. Over the past six months, insider transactions show balanced activity. They sold 204.11 thousand shares across 2 transactions.

Analyst sentiment is bullish. Analyst rating data shows there are 6 Strong Buy ratings, 5 Buy ratings, 5 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $45.00 to $21.00. The high target offers 84.88% upside. The low target suggests -13.72% downside. The mean target is $29.44. This offers 20.95% upside. Caris Life Sciences, Inc. earnings surprise history is a mixed track record. The quarter that ended August 05, 2026, missed forecasts by -139.18%. The prior quarter beat by -1550.0%. Over the last six quarters, Apple has recorded several small beats. These include 157.14% in August 12, 2025.

Caris Life Sciences, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$15.87. This means the shares are trading below this model’s fair value.

Our AI price prediction model suggests that Caris Life Sciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 15.04%, with price expected at $28.00 by September 25, 2026, within a range of $25.58 to $30.34 3-Month Outlook: Projected rise of 12.33%, reaching $27.34 by December 10, 2026, with a range of $26.64 to $27.96. 1-Year Outlook: Projected loss of -44.04%, with price at $13.62 by September 10, 2027, within a range of $12.52 to $15.03.

Caris Life Sciences, Inc. (NASDAQ:CAI) shares are flat -2.63% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Caris Life Sciences, Inc. trading at a premium to the broader market with a P/E of 68.3. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $31.32, suggesting 28.68% upside. Our AI forecast model points to short-term strength (15.04% over two weeks), a medium-term rise (12.33% over three months), and a longer-term loss (-44.04% over one year), with expected trading ranges indicating moderate volatility.

Caris Life Sciences, Inc. trades at a P/E ratio of 68.3, slightly above the S&P 500 average, with a price-to-sales ratio of 7.26 and a price-to-book ratio of 12.14 reflecting a rich premium to book value. The P/FCF stands at 49.01, also above market averages. Compared to sector medians, Caris Life Sciences, Inc. P/S is trading rich, and the P/B is far lower than peers, underscoring the brand and earnings power premium investors assign to the stock.